Dynamics of the Upper and Lower Airway Respiratory Microbiomes Associated With Severe Infant Asthma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeUp to 24
SponsorUniversity Hospital, Rouen
About this trial
Nature of potential dysbiosis, interrelation of the different microbiomes of the respiratory tract, and potential role of the immune system in the pathogenesis of severe asthma in infants, and its evolution under treatment.
Exploring and understanding these data is to improve patient care and discover new therapeutic targets.
The aim is to open up prospects for therapeutic studies, such as the use of azithromycin as an immunomodulator in infant asthma, the results of which are discordant.
Eligibility criteria
Qualifiers
Infants less than 24 months old
Follow-up by a pneumo-pediatrician for severe asthma in infants
Requiring etiological investigations and assessment of severity in day hospitalization, including bronchial fibroscopy (HAS 2009)
Parent informed of the research and having signed consent
Disqualifiers
Prematurity <32 WA
Congenital heart disease with significant left to right shunt
Chronic respiratory disease other than infant asthma (cystic fibrosis, bronchiolitis obliterans)
Antibiotic therapy in progress or administered the seven days preceding the date of inclusion (day hospitalization)
Trial design
Treatments tested in this trial
- Blood sample
- Expectoration
- Nasopharyngeal swab
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov